Lung CancerPhase 2NCT00268489
Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Phase 2 study testing bevacizumab and pemetrexed disodium in people with Lung Cancer, run by Alliance for Clinical Trials in Oncology at 248 sites in United States.
Trial summary
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer
- What is being tested?
- bevacizumab and pemetrexed disodium
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 248 sitesUnited States
- Study dates
- May 2006to Apr 2010
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically or cytologically diagnosed stage IIIB or IV non-small cell lung cancer
- Stage IIIB patients must have pleural effusion
- No symptomatic serosal effusion (grade 2 dyspnea) that is not amenable to drainage
- Mixed histology allowed if all components consistent with non-small cell lung cancer
- Tumors with squamous cell histology feature are allowed
- Must have measurable disease with at least one lesion with a longest diameter accurately measured as ≥ 2.0 cm with conventional techniques or as ≥ 1.0 cm with spiral CT
- Large ( > 4 cm) centrally located lesions or large lesions in close proximity to major blood vessels should receive palliative radiation
- The irradiated lesion should not be a target lesion
- Previously treated with one chemotherapy regimen in the neoadjuvant, adjuvant, or advanced disease setting
- No symptomatic, untreated, or uncontrolled CNS metastases
- CNS metastases treated with prior whole brain radiotherapy allowed
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 12 weeks
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/ mm^3
- Hemoglobin ≥ 9 g/dL
- Bilirubin ≤ 1.5 times upper limit of normal (ULN) or direct bilirubin normal
- AST and ALT ≤ 3 times ULN (5 times ULN if liver has tumor involvement)
- Creatinine clearance ≥ 45 mL/min
- Urine protein:creatinine ratio < 1.0
- Pregnant or nursing women are ineligible
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study participation
- No seizure disorder
- No clinically significant infection
- No other second primary malignancy within the past 5 years except carcinoma in situ of the cervix, non-melanomatous skin cancer, or low-grade (Gleason score ≤ 6) localized prostate cancer
- No hypertension or labile hypertension
- No history of poor compliance with antihypertensive medications
- No angina pectoris
- No congestive heart failure within the past 3 months unless ejection fraction > 40%
- No myocardial infarction within the past 6 months
- No cardiac arrhythmia
- No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
- No active or recent history of hemoptysis
- Hemoptysis resolved > 2 weeks ago with measures such as palliative radiation therapy (i.e., 3,000 cGy over 10 fractions), arteriographic embolization, or endobronchial interventions (e.g., photodynamic therapy or brachytherapy) is acceptable
- No diabetes
- No prior serious, non-healing wounds, ulcers, or bone fractures
- No history of stroke within the past 6 months
- No history of abdominal fistula or gastrointestinal perforation
- No intra-abdominal abscess within the past 6 months
- Not at greater than average risk of bleeding
- No significant traumatic injury within the past 4 weeks
PRIOR CONCURRENT THERAPY:
- No aspirin at doses ≥ 1.3 grams per day within 10 days prior to or 10 days after pemetrexed disodium treatment
- No chemotherapy within the past 3 weeks (6 weeks for mitomycin C or nitrosoureas)
- No immunotherapy or biologic therapy within the past 2 weeks
- No full field radiation therapy within the past 4 weeks or limited field radiation therapy within the past 2 weeks
- The site of previous radiotherapy should have evidence of progressive disease if it is the only site of disease
- No prior post pelvic radiation
- No prior use of pemetrexed disodium
- No prior radiation to > 25% of the marrow cavity
- No major surgery (i.e., laparotomy) or open biopsy within the past 4 weeks
- No minor surgery within the past 2 weeks except insertion of a vascular access device
- No concurrent major surgery
- No other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, or any ancillary therapy considered investigational within the past 4 weeks
- No concurrent use of Hypericum perforatum (St. John's wort)
- No concurrent anticoagulant use
- Low-dose warfarin or heparin for deep venous thrombosis prophylaxis allowed
Trial locations and contacts
248 sites in 1 country.
248 sites in 1 country
United States248 sites
Study site
Alexandria, Minnesota, 56308
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
McFarland Clinic, PC
Ames, Iowa, 50010
Providence Cancer Center
Anchorage, Alaska, 99508
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
Randolph Hospital
Asheboro, North Carolina, 27203-5400
Piedmont Hospital
Atlanta, Georgia, 30309
Northside Hospital Cancer Center
Atlanta, Georgia, 30342-1611
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342-1701
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
Rush-Copley Cancer Care Center
Aurora, Illinois, 60507
WellStar Cobb Hospital
Austell, Georgia, 30106
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
St. Joseph Cancer Center
Bellingham, Washington, 98225
MeritCare Clinic - Bemidji
Bemidji, Minnesota, 56601
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare
Billings, Montana, 59101
Billings Clinic Cancer Center
Billings, Montana, 59107-5100
Deaconess Billings Clinic - Downtown
Billings, Montana, 59107-7000
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Cancer Care Center at Medcenter One Hospital
Bismarck, North Dakota, 58501
Mid Dakota Clinic, PC
Bismarck, North Dakota, 58501
St. Alexius Medical Center
Bismarck, North Dakota, 58502
St. Joseph Medical Center
Bloomington, Illinois, 61701
Cancer Research Center at Boston Medical Center
Boston, Massachusetts, 02118
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Community Hospital
Butte, Montana, 59701
Graham Hospital
Canton, Illinois, 61520
Saint Francis Medical Center
Cape Girardeau, Missouri, 63701
Memorial Hospital
Carthage, Illinois, 62321
Eden Medical Center
Castro Valley, California, 94546
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Riverside Cancer Services
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Danville Regional Medical Center
Danville, Virginia, 24541
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Grady Memorial Hospital
Delaware, Ohio, 43015
Mercy Capitol Hospital
Des Moines, Iowa, 50307
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316-2301
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
CCOP - Duluth
Duluth, Minnesota, 55805
Miller-Dwan Medical Center
Duluth, Minnesota, 55805
St. Mary's - Duluth Clinic Cancer Center
Duluth, Minnesota, 55805
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Eureka Community Hospital
Eureka, Illinois, 61530
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
MeritCare Medical Group
Fargo, North Dakota, 58122
Study site
Fergus Falls, Minnesota, 56537
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Galesburg Clinic
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
Gape Girardeau, Missouri, 63701
Adirondack Cancer Care - Glens Falls
Glens Falls, New York, 12801
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Altru Cancer Center at Altru Hospital
Grand Forks, North Dakota, 58201
Big Sky Oncology
Great Falls, Montana, 59405
Sletten Regional Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
Green Bay Oncology, Limited at St. Vincent Hospital
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Greensboro, North Carolina, 27403-1198
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
Mason District Hospital
Havana, Illinois, 62644
Saint Rose Hospital
Hayward, California, 94545
St. Peter's Hospital
Helena, Montana, 59601
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Hopedale Medical Complex
Hopedale, Illinois, 61747
M.D. Anderson Cancer Center at University of Texas
Houston, Texas, 77030-4009
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Green Bay Oncology, Limited - Iron Mountain
Iron Mountain, Michigan, 49801
Foote Hospital
Jackson, Michigan, 49201
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224
Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois, 60435
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
CCOP - Kansas City
Kansas City, Missouri, 64131
Good Samaritan Cancer Center at Good Samaritan Hospital
Kearney, Nebraska, 68848-1990
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916
Franciscan Skemp Healthcare
La Crosse, Wisconsin, 54601
Fairfield Medical Center
Lancaster, Ohio, 43130
Sparrow Regional Cancer Center
Lansing, Michigan, 48909
Gwinnett Medical Center
Lawrenceville, Georgia, 30045
Southwest Medical Center
Liberal, Kansas, 67901
Meeker County Memorial Hospital
Lichfield, Minnesota, 55355
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
McDonough District Hospital
Macomb, Illinois, 61455
HealthEast Cancer Care at St. John's Hospital
Maplewood, Minnesota, 55109
Minnesota Oncology Hematology, PA at Maplewood Cancer Center
Maplewood, Minnesota, 55109
Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia, 30060
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Mercy Cancer Center at Mercy Medical Center - North Iowa
Mason City, Iowa, 50401
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Middletown Regional Hospital
Middletown, Ohio, 45044
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Virginia Piper Cancer Institute at Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Community Medical Center
Missoula, Montana, 59801
Guardian Oncology and Center for Wellness
Missoula, Montana, 59804
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Chippewa County - Montevideo Hospital
Montevideo, Minnesota, 56265
Ted B. Wahby Cancer Center at Mount Clemens General Hospital
Mount Clemens, Michigan, 48043
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
Highland General Hospital at St. George's University School of Medicine
Oakland, California, 94602
Alta Bates Summit Medical Center - Summit Campus
Oakland, California, 94609
CCOP - Bay Area Tumor Institute
Oakland, California, 94609
Green Bay Oncology, Limited - Oconto Falls
Oconto Falls, Wisconsin, 54154
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Community Hospital of Ottawa
Ottawa, Illinois, 61350
Oncology Hematology Associates of Central Illinois, PC - Ottawa
Ottawa, Illinois, 61350
McCreery Cancer Center at Ottumwa Regional
Ottumwa, Iowa, 52501
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
Regional Cancer Center at Singing River Hospital
Pascagoula, Mississippi, 39581
Cancer Treatment Center at Pekin Hospital
Pekin, Illinois, 61554
Proctor Hospital
Peoria, Illinois, 61614
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61615
Oncology Hematology Associates of Central Illinois, PC - Peoria
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
OSF St. Francis Medical Center
Peoria, Illinois, 61637
Illinois Valley Community Hospital
Peru, Illinois, 61354
Valley Care Medical Center
Pleasanton, California, 94588
Legacy Good Samaritan Hospital & Medical Center Comprehensive Cancer Center
Portland, Oregon, 97210
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213-2967
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Legacy Emanuel Hospital and Health Center & Children's Hospital
Portland, Oregon, 97227
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Perry Memorial Hospital
Princeton, Illinois, 61356
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
Annie Penn Cancer Center
Reidsville, North Carolina, 27320
Reid Hospital & Health Care Services, Incorporated
Richmond, Indiana, 47374
Southern Regional Medical Center
Riverdale, Georgia, 30274-2600
Hubert H. Humphrey Cancer Center at North Memorial Medical Center
Robbinsdale, Minnesota, 55422-2900
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Rutherford Hospital
Rutherfordton, North Carolina, 28139
Seton Cancer Institute - Saginaw
Saginaw, Michigan, 48601
CentraCare Clinic - River Campus
Saint Cloud, Minnesota, 56303
Coborn Cancer Center
Saint Cloud, Minnesota, 56303
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Park Nicollet Health Services
Saint Louis Park, Minnesota, 55416
Regions Hospital Cancer Care Center
Saint Paul, Minnesota, 55101
St. Joseph's Hospital
Saint Paul, Minnesota, 55102
United Hospital
Saint Paul, Minnesota, 55102
Salem Hospital Regional Cancer Care Services
Salem, Oregon, 97309-5014
Cancer Center of Kansas, PA - Salina
Salina, Kansas, 67042
Tammy Walker Cancer Center at Salina Regional Health Center
Salina, Kansas, 67401
Doctors Medical Center - San Pablo Campus
San Pablo, California, 94806
Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
Savannah, Georgia, 31403-3089
Guthrie Cancer Center at Guthrie Clinic Sayre
Sayre, Pennsylvania, 18840
Mayo Clinic Scottsdale
Scottsdale, Arizona, 85259-5499
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98104
Harborview Medical Center
Seattle, Washington, 98104
Minor and James Medical, PLLC
Seattle, Washington, 98104
Group Health Central Hospital
Seattle, Washington, 98112
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
Seattle, Washington, 98122-4307
Polyclinic First Hill
Seattle, Washington, 98122
University Cancer Center at University of Washington Medical Center
Seattle, Washington, 98195-6043
Saint Francis Cancer Center
Shakopee, Minnesota, 55379
Welch Cancer Center at Sheridan Memorial Hospital
Sheridan, Wyoming, 82801
Siouxland Hematology-Oncology Associates, LLP
Sioux City, Iowa, 51101
Siouxland Regional Cancer Center
Sioux City, Iowa, 51101
Mercy Medical Center - Sioux City
Sioux City, Iowa, 51104
St. Luke's Regional Medical Center
Sioux City, Iowa, 51104
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Medical X-Ray Center, PC
Sioux Falls, South Dakota, 57105
Sioux Valley Hospital and University of South Dakota Medical Center
Sioux Falls, South Dakota, 57117-5039
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303
Cancer Care Northwest - Spokane South
Spokane, Washington, 99202
St. Margaret's Hospital
Spring Valley, Illinois, 61362
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65802
St. John's Regional Health Center
Springfield, Missouri, 65804
Hulston Cancer Center at Cox Medical Center South
Springfield, Missouri, 65807
Mercy Medical Center
Springfield, Ohio, 45504
Community Hospital of Springfield and Clark County
Springfield, Ohio, 45505
Missouri Baptist Cancer Center
St Louis, Missouri, 63131
Arch Medical Services, Incorporated at Center for Cancer Care Research
St Louis, Missouri, 63141
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141
David C. Pratt Cancer Center at St. John's Mercy
St Louis, Missouri, 63141
Iredell Memorial Hospital
Statesville, North Carolina, 28677
Green Bay Oncology, Limited - Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235
UVMC Cancer Care Center at Upper Valley Medical Center
Troy, Ohio, 45373-1300
Legacy Meridian Park Hospital
Tualatin, Oregon, 97062
Natalie Warren Bryant Cancer Center at St. Francis Hospital
Tulsa, Oklahoma, 74136
Carle Cancer Center at Carle Foundation Hospital
Urbana, Illinois, 61801
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Pearlman Comprehensive Cancer Center at South Georgia Medical Center
Valdosta, Georgia, 31603
Southwest Washington Medical Center Cancer Center
Vancouver, Washington, 98668
Ridgeview Medical Center
Waconia, Minnesota, 55387
St. John Macomb Hospital
Warren, Michigan, 48093
Cancer Center of Kansas, PA - Wellington
Wellington, Kansas, 67152
Wenatchee Valley Medical Center
Wenatchee, Washington, 98801-2028
Mount Carmel Cancer Services at Mount Carmel St. Ann's Hospital
Westerville, Ohio, 43081
Associates in Womens Health, PA - North Review
Wichita, Kansas, 67203
Cancer Center of Kansas, PA - Medical Arts Tower
Wichita, Kansas, 67208
Cancer Center of Kansas, PA - Wichita
Wichita, Kansas, 67214
CCOP - Wichita
Wichita, Kansas, 67214
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Cancer Center of Kansas, PA - Winfield
Winfield, Kansas, 67156
Minnesota Oncology Hematology, PA - Woodbury
Woodbury, Minnesota, 55125
Woodwinds Health Campus
Woodbury, Minnesota, 55125
United States Air Force Medical Center - Wright-Patterson
Wright-Patterson AFB, Ohio, 45433-5529
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
Xenia, Ohio, 45385
Genesis - Good Samaritan Hospital
Zanesville, Ohio, 43701
About this study
Official title: A Phase II Study of Pemetrexed Disodium (ALIMTA®) Plus Bevacizumab in Patients With Stage IIIB Pleural Effusion or Stage IV Non-Small Cell Lung Cancer (Second-Line Treatment)
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving pemetrexed disodium together with bevacizumab may be an effective treatment for non-small cell lung cancer.
PURPOSE: This phase II trial is studying how well giving pemetrexed disodium together with bevacizumab works in treating patients with stage III or stage IV non-small cell lung cancer.
Read the detailed description
OBJECTIVES:
Primary
- Assess the 3 month progression-free survival rate of the combination of pemetrexed disodium with bevacizumab in a patient population with stage IIIB (due to pleural effusion) or IV non-small cell lung cancer.
Secondary
- Determine the tumor response rate in these patients.
- Determine the effect of pemetrexed disodium in combination with bevacizumab on overall survival and duration of response in these patients.
- Determine the toxicity profile of this drug regimen in these patients.
OUTLINE: This is an open-label, multicenter study.
Patients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 5 years.
- Conditions
- Lung Cancer
- Being tested
- bevacizumab, pemetrexed disodium
- Keywords
- recurrent non-small cell lung cancer, squamous cell lung cancer, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer
- Medical subject headings
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bevacizumabBiological
pemetrexed disodiumDrug
| Study group | Role | What they receive |
|---|---|---|
| pemetrexed + bevacizumab | Experimental | Patients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 5 years. Receives: Biological: bevacizumab; Drug: pemetrexed disodium |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of progression-free patients at 3 months
Measured: at 3 months
Secondary outcomes (5)
Response (complete and partial) as assessed by RECIST criteria
Measured: Up to 5 years
Overall survival
Measured: Up to 5 years
Progression-free survival
Measured: Up to 5 years
Duration of response
Measured: Up to 5 years
Time to treatment failure
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Dec 2005 (estimated)
- Study startMay 2006
- Primary completionMay 2007
- Study completionApr 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Alex A. Adjei, MD, PhD, Study chair, Roswell Park Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00268489
- Sponsor's protocol ID
- NCCTG-N0426
- Other IDs
- NCI-2012-02681, SWOG-N0426, CDR0000456427
- Status last verified
- Jul 2016
- First submitted
- 20 Dec 2005
- Last updated
- 6 Jul 2016
- Results posted
- No
- Data monitoring committee
- No
Publications
Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010 Feb 1;28(4):614-9. doi: 10.1200/JCO.2009.23.6406. Epub 2009 Oct 19.
PubMed 19841321Adjei AA, Mandrekar SJ, Dy GK, et al.: A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. [Abstract] J Clin Oncol 26 (Suppl 15): A-8080, 2008.
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Study of Pemetrexed Disodium (ALIMTA®) Plus Bevacizumab in Patients With Stage IIIB Pleural Effusion or Stage IV Non-Small Cell Lung Cancer (Second-Line Treatment)
- ClinicalTrials.gov ID
- NCT00268489
- Acronym / sponsor ID
- NCCTG-N0426
- Conditions
- Lung Cancer
- Keywords
- recurrent non-small cell lung cancer, squamous cell lung cancer, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- May 2006
- Primary completion
- May 2007 (actual)
- Study completion
- Apr 2010 (actual)
- First posted
- 22 Dec 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving pemetrexed disodium together with bevacizumab may be an effective treatment for non-small cell lung cancer.
PURPOSE: This phase II trial is studying how well giving pemetrexed disodium together with bevacizumab works in treating patients with stage III or stage IV non-small cell lung cancer.
Detailed description
OBJECTIVES:
Primary
- Assess the 3 month progression-free survival rate of the combination of pemetrexed disodium with bevacizumab in a patient population with stage IIIB (due to pleural effusion) or IV non-small cell lung cancer.
Secondary
- Determine the tumor response rate in these patients.
- Determine the effect of pemetrexed disodium in combination with bevacizumab on overall survival and duration of response in these patients.
- Determine the toxicity profile of this drug regimen in these patients.
OUTLINE: This is an open-label, multicenter study.
Patients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| pemetrexed + bevacizumab | Experimental | Biological: bevacizumab, Drug: pemetrexed disodiumPatients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for 5 years. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| bevacizumab | Biological | pemetrexed + bevacizumab |
| pemetrexed disodium | Drug | pemetrexed + bevacizumab |
Primary outcome
Proportion of progression-free patients at 3 months
Time frame: at 3 months
5 secondary outcomes
Response (complete and partial) as assessed by RECIST criteria
Time frame: Up to 5 years
Overall survival
Time frame: Up to 5 years
Progression-free survival
Time frame: Up to 5 years
Duration of response
Time frame: Up to 5 years
Time to treatment failure
Time frame: Up to 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2016.
- Results publication: PubMed 19841321Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010 Feb 1;28(4):614-9. doi: 10.1200/JCO.2009.23.6406. Epub 2009 Oct 19.
- Results publicationAdjei AA, Mandrekar SJ, Dy GK, et al.: A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. [Abstract] J Clin Oncol 26 (Suppl 15): A-8080, 2008.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alex A. Adjei, MD, PhD study chair
Roswell Park Cancer Institute
248 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing bevacizumab and pemetrexed disodium in people with Lung Cancer, run by Alliance for Clinical Trials in Oncology at 248 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 248 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of progression-free patients at 3 months (time frame: at 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00268489, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2016.